Scholar Rock Holding (SRRK) Total Liabilities (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Total Liabilities of $259.2 million for Q1 2026, up 172.25% year-over-year from $95.2 million in Q1 2025, and up 63.27% quarter-over-quarter from $158.8 million in Q4 2025.
Scholar Rock Holding (SRRK) Total Liabilities (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Total Liabilities history runs 10 years deep, the most recent figure standing at $259.2 million for Q1 2026.
- In Q1 2026, Total Liabilities rose 172.25% year-over-year to $259.2 million; the TTM figure through Mar 2026 stood at $259.2 million (up 172.25% YoY), while the FY2025 annual figure was $158.8 million, up 49.39% from the prior year.
- Total Liabilities for Q1 2026 stood at $259.2 million, up from $158.8 million in the prior quarter.
- The five-year high for Total Liabilities was $259.2 million in Q1 2026, with the low at $82.4 million in Q2 2023.
- The 5-year median for Total Liabilities is $95.2 million (2025), against an average of $111.3 million.
- The sharpest annual moves came in 2022 and 2026: Total Liabilities dropped 26.02% in 2022, then jumped 172.25% in 2026.
- Scholar Rock Holding's Total Liabilities stood at $97.9 million in 2022, then decreased by 12.37% to $85.8 million in 2023, then grew by 23.85% to $106.3 million in 2024, then jumped by 49.39% to $158.8 million in 2025, then jumped by 63.27% to $259.2 million in 2026.
- Business Quant data shows SRRK's Total Liabilities at $259.2 million in Q1 2026, $158.8 million in Q4 2025, and $166.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - | 269.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 269.76 Mn |
| Mar 31, 2026 | 259.24 Mn |
| Dec 31, 2025 | 158.78 Mn |
| Sep 30, 2025 | 166.72 Mn |
| Jun 30, 2025 | 106.75 Mn |
| Mar 31, 2025 | 95.22 Mn |
| Dec 31, 2024 | 106.29 Mn |
| Sep 30, 2024 | 99.94 Mn |
| Jun 30, 2024 | 93.25 Mn |
| Mar 31, 2024 | 84.51 Mn |
| Dec 31, 2023 | 85.82 Mn |
| Sep 30, 2023 | 83.02 Mn |
| Jun 30, 2023 | 82.40 Mn |
| Mar 31, 2023 | 86.07 Mn |
| Dec 31, 2022 | 97.93 Mn |
| Sep 30, 2022 | 97.04 Mn |
| Jun 30, 2022 | 94.62 Mn |
| Mar 31, 2022 | 94.66 Mn |
| Dec 31, 2021 | 132.37 Mn |
| Sep 30, 2021 | 111.13 Mn |